Reduces elevated serum total and low-density lipoprotein (LDL) cholesterol. Sold as Flavored Colestid, Colestid. Every FDA application for this active ingredient: 2 branded and 7 generic.
As of Nov 15, 2026, FDA lists 9 applications for Colestipol Hydrochloride (sold as Flavored Colestid, Colestid), first approved Apr 4, 1977, with 0 new uses approved and 0 published complete response letters.
| Colestipol HCl | Part D | $46.6M | +4% | 182,215 |
| Colestid | Part D | $29K | -28% | 67 |
| Apr 4, 1977 | Flavored Colestid, ColestidNDA 17563 · New molecular entity | Pfizer | 21 | Marketed |
| Jul 19, 1994 | ColestidNDA 20222 · New dosage form | Pfizer | 4 | Marketed |
| May 2, 2006 | Colestipol HydrochlorideANDA 77277 | Impax Labs | 0 | Discontinued |
| Oct 24, 2006 | Colestipol HydrochlorideANDA 77510 | Impax Labs | 4 | Marketed |
| Mar 10, 2022 | Colestipol HydrochlorideANDA 215223 | Zydus Pharms | 0 | Marketed |
| Mar 10, 2023 | Colestipol HydrochlorideANDA 216517 | Ani Pharms | 0 | Marketed |
| Aug 16, 2024 | Colestipol HydrochlorideANDA 217667 | Edenbridge Pharms | 0 | Marketed |
| Dec 3, 2024 | Colestipol HydrochlorideANDA 217462 | Riconpharma LLC | 0 | Marketed |
| Sep 15, 2025 | Colestipol HydrochlorideANDA 220012 | Macleods Pharms | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer
Impax Labs
Zydus Pharms